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Abstract
Background: Both HIV and TB cause a state of heightened immune activation. Immune activation in HIV is associated with
progression to AIDS. Prior studies, focusing on persons with advanced HIV, have shown no decline in markers of cellular
activation in response to TB therapy alone.
Methodology: This prospective cohort study, composed of participants within a larger phase 3 open-label randomized
controlled clinical trial, measured the impact of TB treatment on immune activation in persons with non-advanced HIV
infection (CD4.350 cells/mm3) and pulmonary TB. HIV load, CD4 count, and markers of immune activation (CD38 and HLA-
DR on CD4 and CD8 T cells) were measured prior to starting, during, and for 6 months after completion of standard 6 month
anti-tuberculosis (TB) therapy in 38 HIV infected Ugandans with smear and culture confirmed pulmonary TB.
Results: Expression of CD38, and co-expression of CD38 and HLA-DR, on CD8 cells declined significantly within 3 months of
starting standard TB therapy in the absence of anti-retroviral therapy, and remained suppressed for 6 months after
completion of therapy. In contrast, HIV load and CD4 count remained unchanged throughout the study period.
Conclusion: TB therapy leads to measurable decreases in immune activation in persons with HIV/TB co-infection and CD4
counts .350 cells/mm3.
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Introduction
Cellular markers of immune activation, CD38 and HLA-DR on
CD4 and CD8 T lymphocytes, are elevated in HIV infected
individuals. Opportunistic infections such as tuberculosis (TB) lead
to further increases in immune activation and stimulate HIV viral
replication [1]. Sulkowski et al. showed that successful treatment of
opportunistic infections, excluding TB, led to declines in HIV load
and decreased immune activation [2]. One would predict that
treatment of TB would also lead to declines in HIV load and
increases in CD4 count, but studies addressing this question have
been contradictory. Studies within the United States and Europe
have shown a decrease in HIV load in response to TB therapy
[3,4]. In contrast, studies from sub-Saharan Africa have failed to
see declines in HIV load after several months of TB therapy [5–7].
It is a similar story for CD4 counts. In HIV negative individuals
active TB disease induces CD4 lymphopenia which is respon-
sive to TB therapy [8]. However, in persons with HIV/TB co-
infection, treatment of TB has not impacted CD4 counts [5,6].
Immune activation has been implicated as a critical driver of
HIV disease progression. Expression of CD38 on CD8 T cells has
been shown to be a strong predictor of HIV progression and death
[9]. Despite multiple studies demonstrating increased CD38 and/
or HLA-DR expression on CD8 T cells in persons with or without
HIV co-infection during active TB there are few studies showing
declines in these cellular markers of immune activation in response
to TB treatment. Our earlier studies have shown that TB exerts its
greatest effect on survival in persons with early stage HIV [10]. We
therefore hypothesized that TB therapy alone in TB patients with
less advanced HIV would lead to measurable declines in immune
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activation and corresponding declines in HIV load. To test this
hypothesis we prospectively followed a cohort of 38 HIV positive
persons with baseline CD4 counts .350 cells/mm3 in Uganda
who had smear and culture confirmed pulmonary TB and was
placed on standard anti-TB therapy.
Materials and Methods
We present a cohort study of participants in a phase 3 open-
labeled randomized clinical trial measuring the impact of early
HAART combined with standard TB therapy versus TB therapy
alone in persons with pulmonary TB and HIV infection with high
CD4 counts. Subjects, between the ages of 18 and 60, were
recruited from the Uganda-Case Western Reserve University
Research Collaboration within the Mulago Hospital Complex in
Kampala, Uganda. All subjects gave written informed consent.
This sub-study focused on the anti-retroviral therapy naı¨ve HIV
positive persons with smear positive pulmonary TB and CD4
counts .350 cells/mm3 who were started on a standard regimen
of directly observed TB therapy (two months of isoniazid,
rifampin, pyrazinamide, and ethambutol, followed by four months
of isoniazid and rifampin). Mid-way through study enrollment
daily cotrimoxazole was added in response to new international
guidelines. At the 3, 6, 9, and 12 month study visits 84%, 92%,
Figure 1. Representative Flow cytometric approach to define immune activation of CD8 T cells. A. Gating on lymphocytes based on
forward and side scatter properties. B. Gating on CD8 T cells. C. Expression of CD38 and HLA-DR on CD8 T cells.
doi:10.1371/journal.pone.0009138.g001
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84%, and 87% of the participants were taking daily cotrimoxazole.
The study protocol was approved by the institutional review
boards of Case Western Reserve University (CWRU), University
of California at San Francisco, the Joint Clinical Research Center
in Kampala, Uganda and the Ugandan National Council for
Science and Technology (Figures S1–S3).
Enrollment for the larger clinical trial began in October 2004.
The protocol for this trial, supporting CONSORT checklist and
flow diagram of enrollment are available as supporting informa-
tion (Checklist S1, Protocol S1, Figure S4). In this substudy, data
was accrued between March 2006 and February 2009. Partici-
pants gave informed consent and had blood obtained for immune
analysis at baseline, 3, 6, 9, and 12 months after enrollment. All
persons with flow data at baseline, 3 and/or 6 months, and 9 and/
or 12 months were included in the analysis (n = 38). All patients
completed TB treatment by month 6. Immunologic studies were
performed at the Joint Clinical Research Center in Kampala,
Uganda.
Plasma HIV-RNA copy levels (HIV load) were measured using
Amplicor quantitative restriction transcriptase-polymerase chain
reaction assay (Roche Amplicor 1.5) according to manufacturer
instructions. The lower limit of detection of the assay was
400 copies/mm3.
Whole blood was collected in sodium heparin tubes and 200 ul
was aliquotted to each of the 12675 mm test tubes. For flow
cytometry the following antibodies were used: anti-CD4 allophy-
cocyananin (APC), anti-CD8 APC, anti-HLA-DR phycoerythrin
(PE), and anti-CD38 phycoerythrin Cy5 (PE Cy5). Mouse
monoclonal isotypic controls conjugated with PE, PE Cy5, and
APC were used to determine non-specific binding and to set gating
boundaries. All antibodies were obtained from BD Pharmingen
(San Diego, California).
Using 4 color flow cytometry (Becton Dickinson FACSCalibur)
25–50,000 cells were analyzed for each condition. Initial gating
was on the lymphocytes based on forward and side scatter. CD4 or
CD8 T cell populations were then determined. T cells were then
evaluated for the percentage of cells expressing HLA-DR and
CD38 (Figure 1).
Non-parametric rank tests were performed to compare median
changes in immune activation from baseline to months 3, 6,
9, and 12; and to compare levels at 6 months with 9 and 12
months (the period after TB therapy was completed). Data were
stratified by cotrimoxazole use to determine its effect on immune
activation at each time point. All analyses were performed using
Statistical Analysis Software (SAS) Version 9.1 (SAS Institute,
Cary, NC).
Results
Of the 38 HIV infected persons with sputum smear and culture
confirmed pulmonary TB the mean age was 32 years (range 19–
54) and 24 were males (63%) and 14 female. The median baseline
HIV load was 4.4 log10 copies/ml (range 2.0–5.9 log10 copies/
mL) and the median CD4 count was 610 cells/mm3 (range 374–
1368). 36 of 38 persons were sputum culture negative at 2 months,
and all 38 were culture negative by 4 months while on TB
treatment. Among these 38 persons there was only one death
which occurred 10 months after completion of TB therapy.
There was no significant change in median HIV log10 load as
compared to baseline at 3 (4.3 log10 copies/mL), 6 (4.5 log10 copies/
mL), 9 months (4.6 log10 copies/mL), or 12 months (4.4 log10 copies/
mL) (Figure 2A). Additionally there was no significant change in
median CD4 count from a baseline value of 610 cells/mm3, to
637 cells/mm3 at 3 months, 540 cells/mm3 at 6 months, 602 cells/
mm3 at 9 months, and 608 cells/mm3 at 12 months. (Figure 2B).
The change in median percentage of CD4 cells expressing
CD38 was unchanged from baseline (32%), to 3 (31%), 6 (26%),
and 9 months (29%), but measured a significant decline at 12
months (24%) (Figure 3A). The percentage of CD4 cells that were
double positive, expressing both HLA-DR and CD38, declined
from a baseline value of 8% to 6% (P,.05) at 3 months, 5%
(P,.05) at 6 months, at 9 months the change from baseline was no
longer significant (6%) (P..05), but regained significance at 12
months (4%) (P,.01) (Figure 3B).
The median percentage of CD8 cells expressing CD38 declined
from 34% at baseline to 20% (P,.01) at 3 months, 22% (P,.01) at
Figure 2. Change in HIV Load and CD4 Counts in response to TB therapy. A. HIV log10 RNA viral loads on standard TB therapy at baseline, 3,
6, 9, and 12 months. B. CD4 counts at baseline, 3, 6, 9, and 12 months (n = 38 for all time points). The boxes indicate the interquartile ranges, the
horizontal lines transecting the boxes indicate the medians, and the whiskers indicate the highest and lowest values. All values with P..05.
doi:10.1371/journal.pone.0009138.g002
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6 months, to 25% (P,.05) at 9 months, to 18% at 12 months
(P,.001) (Figure 3C). The percentage of CD8 cells that were
double positive, expressing both HLA-DR and CD38, declined
from 26% at baseline to 16% (P,.01) at 3 months, 15% (P,.01)
at 6 months, to 18% (P,.05) at 9 months, and to 13% at 12
months (P,.001) (Figure 3D). HLA-DR expression alone on CD4
and CD8 cells was not significantly changed from baseline. Thus,
the expression of CD38 and the co-expression of CD38/HLA-DR
on CD8 cells were strongly affected by TB therapy while
decreased expression of these markers on CD4 cells was less
pronounced.
The primary analysis used for figures 2 and 3 was Wilcoxon
rank test for non-parametric values. Data sets were also analyzed
by Sign test which confirmed all values of statistical significance.
Additionally, stratified analysis showed no significant impact of
cotrimoxazole use on immune activation of CD8 T cells. When
accounting for cotrimoxazole use the combined expression of
CD38/HLA-DR on CD4 T cells was no longer significant at 6
months but remained so at 12 months.
Discussion
In this prospective cohort study of persons with HIV (CD4
counts.350 cells/mm3) and pulmonary TB we measured a
significant decline in CD8 T cell immune activation that persisted
for at least 6 months after completion of TB therapy. We did not
observe decreased HIV load or increased CD4 counts in response
to TB therapy.
Both HIV and MTB infection cause immune activation. How
HIV infection leads to chronic immune activation is poorly
understood. Depletion of gut mucosal lymphocytes and transuda-
tion of LPS into the systemic circulation has been postulated by
some. Alternatively, HIV and its viral gene products can directly
activate the immune system [11]. In active TB, macrophages
release pro-inflammatory cytokines (IL-1, IL-6, TNF-a) in
response to mycobacterial proteins and glycolipids, resulting in
CD4 and CD8 T lymphocyte recruitment and activation at the
site of infection and systemically [12]. CD38 and HLA-DR
expression on CD8 cells, markers of immune activation, are higher
Figure 3. Change in immune activation in response to TB therapy. Percentage expression of CD38 (A,C), and CD38/HLA-DR (B,D) on CD4 and
CD8 T cells at baseline, 3, 6, 9, and 12 months. The boxes indicate the interquartile ranges, the horizontal lines transecting the boxes indicate the
medians, and the whiskers indicate the highest and lowest values. Significant P values (,.05) are indicated.
doi:10.1371/journal.pone.0009138.g003
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in HIV/TB co-infection than in persons with either HIV infection
or TB alone [13].
In HIV/TB co-infection, TB leads to increased HIV viral
replication both in the lungs and systemically. TNF-a produced
in response to mycobacterial proteins induces HIV viral
replication through nuclear factor kappa b (NFK-b) binding to
the 59 end of the long terminal repeat of HIV [12]. Immune
activation and inflammatory cytokines induced by opportunis-
tic infections such as MTB can drive HIV viral replication.
Thus one would predict that TB treatment should lead to a
decrease in immune activation and a corresponding decline in
HIV load.
Our finding that reduced immune activation did not result in a
reduction in HIV load suggests that there may not be a linear
relationship between immune activation and viral replication in
HIV/TB. The anti-inflammatory/-infective properties of cotri-
moxazole and rifampin could contribute to decreasing immune
activation. However, when data was stratified for cotrimoxazole
use there was no impact on CD38 expression. The lack of a
rebound six months after completing TB therapy argues against a
role for rifampin. The possible disconnect between immune
activation and HIV load is further supported by our observation
that up to 24% of HIV/TB co-infected Ugandans have low
baseline HIV viral loads that are independent of CD4 counts and
severity of TB [14]. While studies performed in the United States
and Great Britain show that TB treatment decreases HIV load
[3,4], our study is consistent with similar work from sub-Saharan
Africa that found no change [6,7].
Our most striking finding was a clear decline in immune
activation seen as early as 3 months into treatment. Percentage
expression of both CD38 alone and co-expression of CD38/HLA-
DR on CD8 T cells was significantly decreased after 3 and 6
months of standard TB therapy and remained decreased for at
least 6 months after completion of therapy. Additionally, there was
a trend towards decreased expression of CD38 and HLA-DR on
CD4 T cells. These findings are at odds with Morris et al. who
failed to see a decline in immune activation in their sub-Saharan
HIV/TB co-infected cohort [6]. Although both cohorts were in
sub-Saharan Africa, our cohort had much higher CD4 counts at
baseline (mean of 642 cells/mm3) compared to the Morris cohort
(mean CD4 count of 184 cells/mm3). It is quite possible that
normal regulatory patterns that induce macrophages and T cells to
produce pro-inflammatory cytokines are disrupted in advanced
HIV disease and are less likely to normalize in response to TB
therapy [15]. In contrast, in less advanced HIV infection TB
therapy may be more likely to re-establish normal cytokine
responses leading to a corresponding decline in immune acti-
vation. Epidemiologic studies have shown that treatment of TB
has a greater impact on survival in HIV infected persons with
higher CD4 counts (.200 cells/mm3), and little impact on those
with more advanced HIV disease [10].
The failure of CD4 counts to increase in response to TB therapy
is also intriguing. TB in non-HIV infected persons induces
lymphopenia that returns to normal within one month of
treatment [8]. This response may be offset by the increased T
cell apoptosis in HIV/TB [12]. Our findings are in-line with
others who have shown no increase in CD4 counts with TB
therapy in HIV infected individuals [5,6]. Conversely one might
argue that the relatively stable CD4 counts over 1 year, as opposed
to a steady decline, are indirect evidence for further immunologic
benefit.
Limitations of our study include the lack of control group and
limited number of patients. The ideal control group would be
similar persons with HIV/TB co-infection that are followed and
do not receive TB treatment. For obvious reasons this study
will not be performed. Alternatively, one might compare our
group to those with HIV infection alone, but these persons even
if having similar CD4 and HIV loads at baseline are unlikely
to have similar baseline levels of immune activation [16]. Despite
following only 38 persons longitudinally we were able to find
a measurable decline in immune activation. One cannot exclude
the possibility that our study lacked the power to detect
more subtle, but still significant changes in HIV load and CD4
counts.
In conclusion, we found that TB therapy in HIV/TB co-
infected persons with CD4 counts .350 cells/mm3 leads to
significant declines in immune activation of CD8 T cells with-
out a measurable impact on HIV load or CD4 counts. Our
findings suggest that declines in immune activation rather than
changes in HIV load or CD4 count may explain prior
epidemiologic observations that TB treatment leads to survival
benefits in HIV/TB co-infected patients with less advanced HIV
disease.
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